Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
I may try to register for tomorrow's EGFR workshop. FLevent.on24.com/eventRegistration/Even...
Aandeel is al even rond de 4.80 aan het zweven. Lijkt me ook enigzins raar dat met deze outlook niet meerdere de sprong wagen om mee te investeren. Ik ken het risico dat het bedrijf snel door cash faat, maar in mijn ogen is de upside toch immens.
Here is a link to the MSK webinar on EGFR work flow. I thought it made a pretty good case for incorporating Idylla EGFR analyses into the workflow. It would be helpful if they can develops a procedure for resolving the analyses on stained cytology smear samples (removal of stain etc.). Hopefully the recommended flow charts become widely implemented. FLevent.on24.com/wcc/r/2289516/25F8119E...
AZN is jumping in the after hours on the release of an ASCO paper (on-line this year) on its NSCLC Drug Tagrisso.finance.yahoo.com/news/astrazeneca-un... BCART has partnered with AZN for both the solid and liquid EGFR tests for use as a CDx for this drug. Since this is early stage cancer with great survival numbers 89%, there looks to be a great market for the drug. Combine this with last weeks presentation by MSK and things look good for BCART's worldwide entry into the lung cancer market. FL
If the ctEGFR study goes well, I'd expect an announcement that they are extending the agreement to China. FL
Flatlander schreef op 29 mei 2020 00:34 :
If the ctEGFR study goes well, I'd expect an announcement that they are extending the agreement to China.
FL
Hi Flatlander Which timeframe are we looking at for this study and announcement? It seems we have a resistancelevel around 4.75. I'm back in track after I took some profit past month. Thank you for your updates. Kind regards Nestel
FL Your thoughts, please, on the following: Do you think we are in for a positive surprise at the H1 numbers (due to the accelerated move to POC because of Covid-19) or a negative surprise because of the reduced access to hospitals of the sales teams? Have any of the other biotechs that you follow reported on this issue of limited Covid-19 access to hospitals? Concerning the high projected cash burn, I wonder if it cannot be explained by some sort of provision for Covid-19 (in stead of a large one time investment, which was my initial thought). Maybe there is room for a positive surprise, then. Concerning ctEGFR, I find it strange that, considering the sales potential of Tagrisso, no trajectory has yet been set in motion to get CE IVD approval. Or did I miss something? What study are you referring to? BL
Nestel I'm not the person to follow when it comes to timing. I'm on record on this board saying I thought OncoTypeDx Breast was a late 2019 launch. If you look at the ASCO abstracts there are a few EGFR related studies out of China. I think that bodes well for registration approvals later in the year. Because they locked down hard in January, I think their oncology treatments are getting back to normal. Europe and the US are behind. Because of the smoking rates in Asia and the incidence of EGFR mutations, I think this will be great market for Idylla. The Chinese claim they average 3-7 days for NGS data TAT. However, there are still issues where recovering actionable NGS results is an issue. I think there is a nice role for Idylla corroborating targets. The Septicyte/Covid data is probably a 2nd half story but it may also move the needle. There are a lot of moving parts that could impact SP both positively and a few negatively. This is a very trying time. As I said before, I anticipate that some MDx firms do not survive it. In the short run they may have added COVID testing that helps offset demand that eroded elsewhere. As the COVID testing begins to decline there will be a scramble to raise cash. The thing to keep your eye on is what firms are gaining oncology MDx market share. I want to see if the pandemic acts as an accelerant for the Idylla streamed lined work flow. I think you will probably get a good re-entry point during the summer before the news flow for the 2nd half picks up. FL
brightlight schreef op 29 mei 2020 12:25 :
FL
Your thoughts, please, on the following:
Do you think we are in for a positive surprise at the H1 numbers (due to the accelerated move to POC because of Covid-19) or a negative surprise because of the reduced access to hospitals of the sales teams? Have any of the other biotechs that you follow reported on this issue of limited Covid-19 access to hospitals?
Concerning the high projected cash burn, I wonder if it cannot be explained by some sort of provision for Covid-19 (in stead of a large one time investment, which was my initial thought). Maybe there is room for a positive surprise, then.
Concerning ctEGFR, I find it strange that, considering the sales potential of Tagrisso, no trajectory has yet been set in motion to get CE IVD approval. Or did I miss something? What study are you referring to?
BL
BL In the U.S. I'm hearing that since March that oncology procedures (colonoscopies, breast lumpectomies, biopsies, etc.) are down 70%. GenomeWeb documents that the majority of oncology MDx companies are seeing much lower test volume and anticipate it will continue into the 2nd quarter. This is not the makings of a great first half for BCART on an absolute basis. However, as discussed in the previous post, emergencies often accelerate trends. BCART could be a huge winner if the relative comparisons are better than competitors (i.e., BCART shows evidence of gaining market share). If labs, hospitals, clinics etc. increase their Idylla usage because it simplifies testing in an age of social distancing, it could be setting usage trends that thrive long after the pandemic is over. There will likely be meager new console placements until the 2nd half. In the 2nd ha Septicyte/Covid may act as a driver for new console placements. Similarly Asia registration approvals may also drive placements (since they seem to be managing the pandemic in a way that is allowing a quicker return to normalcy). I hope you are right that the cash usage is directed toward the COVID launch. There is still critical need for an accurate fast test. Dr. Fauci has cast doubt on the Abbot IDNow test and referenced that Cepheid is a much more accurate platform. I suspect that Idylla can reach similar accuracy levels. I'm hopeful for the placement of Idylla systems in ICUs. Pediatric and neo natal ICUs have especially been identified as having an intense need for a fast sepsis test. With the lower blood draw requirements of septicyte rapid, it looks like it could be a good fit for this market. So yes I think there is room for a surprise, but it is probably a 2nd half story. The Master collaboration agreement with AZN includes a study evaluating how rapid ct EGFR characterization might benefit the launch of Tagrisso. The MSK webinar that ran last week discussed the use of Idylla to help resolve difficult (low volume cytology samples). Based on Dr. Maria Arcila indicated that about 25% of the NGS testing could be cancelled in cases where Idylla yielded positive mutation results (i.e., NGS testing could be avoided, thus saving costs). NGS is more sensitive, so if Idylla yields negative results, potential exists that the mutations are present but below Idyllas sensitivity range, so negative samples would still need to be submitted for NGS analysis. I'm sure AZN is looking at this relationship as a means of accelerating Tagrisso scripts. Got to go. FLwww.globenewswire.com/news-release/20...
Attached is a link to a really long article on COVID in the US, The 1st third of the article deals with MDx and has several points that are relevant to BCART, The sections on contact tracing and treatments/vaccines can probably be skipped.finance.yahoo.com/news/coronavirus-va... It is important to recognize that much the PCR equipment being referenced (Cobas etc) is also used for oncology MDx so the bottlenecks affect both Covid and cancer testing. I found this section especially interesting. "Lack of Centralized IT and Logistics Capabilities We think this, perhaps, is the most significant factor in the near and mid-term that prevents us from turning our theoretical test capacity into reality. Getting the specimen from the healthcare provider to a lab with the appropriate equipment platform that has space in its overnight batches is difficult without a centralized information system. Then, take hundreds of thousands of specimens, multiplied by thousands of healthcare providers, multiplied by hundreds of labs, and by a handful of major equipment platforms. This quickly turns into a massive matching game to get each specimen to the right lab at the right time. " Idylla definitely alleviates many of these problems. Regards FL
Interesting interview with Dr. Rolland Carlson, the founder of Immunexpress.www.appliedclinicaltrialsonline.com/c... This part is especially pertinent to BCART. MA: What is the value of this diagnostic to physicians and patients? Especially during times, like now with COVID and increasing patient volumes in the ICU? RC: Our test is designed for people with a strong suspicion of sepsis. However, 44% of the time, those patients suspected of sepsis don’t actually have sepsis. Regardless, all patients suspected of sepsis are admitted to the ICU, and there just aren't enough ICU beds to compensate for these patients. This problem is now exacerbated by the COVID pandemic. So, the utility of our test is extremely valuable right now. Additionally, patients with COVID are ultimately dying from a virally-induced systemic inflammatory response: this is viral sepsis. When a COVID-positive patient comes into the ER, they are assessed over a series of hours and many times are sent home. This is where our tests could have high utility. Our test can detect whether or not a patient is starting to go down that true sepsis cascade due to the virus. Our test is designed to pick up viral induced sepsis, bacterial induced sepsis and fungal induced sepsis. For COVID patients, we're seeing that the cascade starts with viral sepsis, but could lead to a bacterial coinfection. Because we measure the patient’s gene activation to a potential sepsis event, we are not limited to only finding the invading pathogen. Of course, if a COVID-positive patient is determined to have sepsis, he or she would not be discharged, but admitted into the ICU. We are modifying our clinical trials right now at the request of the U.S. government to make sure that we can include COVID-positive patients. We've submitted a grant to the U.S. government for accelerated emergency use authorization of our test for COVID triage. My take: The Bad News: The US approval is likely delayed since the clinical trial has been altered to include triage of COVID positive Sepsis cases. The Good News: Positive results from such a clinical trial would make this an extremely important test. I don't know about the EU but numerous COVID positive patients have been discharged from emergency rooms only to either die at home or return to the hospital a short time later. This could be very big. The trials should have no trouble enrolling sufficient patients,so I think we could have results and an EUA furing the 3rd quarter. Regards FL
Looks like BCART has ramped up its distribution network throughout the world. Most of western Europe is served by BCART out of Belgium but they identify alot of outside distribution partners throughout the world. My guess is that this is in anticipation of Septicyte Rapid product launch in the near future. Someone out there want to go through the list and check it against the list of countries that follow the EU marking of a new MDx product. I think this is a statement of much larger anticipated geographically distributed demand compared to its Oncology MDx products. Unfortunately, we will only have a few weeks of distribution during the 2nd quarter, so we might have to wait a while to track the sales numbers associated with this new product. FL www.biocartis.com/en/in-your-country
FL, Attached is a list of countries that follow EU marking and the respective distributors, as you requested. Not sure what you want to do with that list. BL
BL Just trying to see if the distribution contact network was established recently in support of the Septicyte launch. I'd expect that there will be technical papers being issued in the near future that details the use of Idylla for COVID triage. FL
Invetech POC best practices. As posted previously, I'm pretty sure this is BCARTS contracted manufacturing partner for the consoles. I tried to post the PDF but the file size was too big, so use the link. The graph on page 19 suggests that BCART can still cut the cost of each cartridge in half if they can reach full capacity. In the graph case 1.2 million cartridges per year. FLwww.genomeweb.com/resources/white-pap...
Filmpje over de werking van Idyllam.youtube.com/watch?v=xl7MKWJTbUQ
Phoene schreef op 6 juni 2020 01:40 :
Filmpje over de werking van Idylla
m.youtube.com/watch?v=xl7MKWJTbUQ heel interessant
Heeft er iemand een idee wat de stand van zaken is met het oog op de eigen opstart van het sales team in de US? Ik zie geen Sales vacatures openstaan in Amerika. Verwachten we eigenlijk iets van trigger voor we de halfjaarlijkse resultaten, begin september, krijgen? We dobberen nu al ongeveer een maand rond de 4.6-4.9.
Er is wel degelijk een team verantwoordelijk voor de USA, zowel naar sales, r&d, technische ondersteuning. Een week geleden verscheen op de linkedin pagina van Biocartis een foto van het US-team met als titel “The Biocartis US team is still going strong” Het is biotech dus niets valt uit te sluiten op vlak van nieuwsberichten zowel positief als ook negatief natuurlijk.
I'm quite optimistic about the launch of Septicyte Rapid. I've done a good deal of research and I believe the test is ideally positioned for Covid triage use. Because the test is Host Response RNA based rather than pathogen based, it is directed at the cytokine storm that is at the root of the Covid deaths. Almost all Covid deaths are attributed to sepsis resulting from this cytokine storm. In the switch from Septicyte Lab to Septicyte Rapid Biocartis has addressed two of the use limiting factors identified in the attached review. cmr.asm.org/content/31/2/e00089-17 1st the Rapid test may now be run on 0.9 ml of blood making it appropriate for all age groups including infants. 2nd the TAT has been cut from 4 to 6 hours to 65 minutes. Combine these factors with the ease of use and I think Septicyte could well be the "Killer Ap" that drives console placements. I have previously hypothesized that BCART suffered from a Chicken and Egg problem. In order to attract new partnerships the number of console placements needs to increase so as to increase the attractiveness of the platform. But to drive console placements, Idylla needs "a must have assay" that provides something not available on other platforms. Septicyte especially during the pandemic fits that bill. If by mid 2021 we are talking about console placements well in excess of 2500, the system will have the kind of momentum that attracts partners and new content. My review of the history of Cepheid's Gene Expert launch found that pandemic fears (H1N1, TB, etc.) often drove sales. Initially, I did not think this would help BCART since they were focusing on oncology, but septicyte has the potential to place a lot of units in emergency rooms and ICU's. After this pandemic, the equipment utilization for other assays will likely increase. If I'm right about increased console placement, BCART will need to target a cross marketing campaign in the future to foster increased oncology assay usage. I always though that OncoType Dx would be the driver for system uptake. I now think that driver is Septicyte. FL
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee